ArriVent BioPharma Quarterly Cash Flow Statement
NASDAQ: AVBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.73+0.02 (+0.12%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ArriVent BioPharma free cash flow
In the quarter ended Jun 30, 2026, ArriVent BioPharma generated -$39.6 million of operating cash flow. That left free cash flow of -$39.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
ArriVent BioPharma cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -49.89M | -43.32M | -35.54M | -34.98M | -31.40M | -64.39M | -20.63M | -20.56M | -21.87M | -17.42M | -21.19M | -14.40M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | -515.00K | -559.00K | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 6.67M | 5.49M | 3.22M | 3.72M | 3.31M | 2.27M | 952.00K | 866.00K | 765.00K | 625.00K | 319.00K | 217.00K |
| Change in Working Capital | 2.68M | -984.00K | 4.70M | -4.53M | 1.97M | -5.89M | 2.10M | 3.06M | 1.78M | -1.34M | 5.97M | -1.27M |
| Operating Cash Flow | -39.58M | -41.89M | -30.66M | -35.80M | -26.12M | -68.01M | -16.15M | -16.34M | -19.09M | -18.63M | -14.91M | -15.44M |
| Investing Cash Flow | 46.07M | 3.58M | -71.20M | -50.76M | 13.91M | 36.82M | — | — | — | — | — | 0 |
| Financing Cash Flow | 86.09M | 54.87M | 34.73M | 86.47M | 75.11M | 6.76M | 55.00K | 531.00K | 363.00K | 185.63M | -1.06M | -1.03M |
| Net Change in Cash | 92.58M | 16.56M | -67.13M | -93.00K | 62.90M | -24.43M | -208.56M | -15.81M | -18.72M | 167.00M | 9.03M | -16.48M |
| Free Cash Flow | -39.58M | -41.89M | -30.66M | -35.80M | -26.12M | -68.01M | -16.15M | -16.34M | -19.09M | -18.63M | -14.91M | -15.44M |
This table shows 12 quarterly periods of ArriVent BioPharma's cash flow statement, from Q2 2026 back to Q3 2023, across 9 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AVBP's reporting calendar. What is a cash flow statement?